A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. 2010

Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
Shiraz University of Medical Sciences & Health Services, Shiraz, Iran.

OBJECTIVE The aim of this study was to compare the effects of bromocriptine versus cabergoline on pregnancy in hyperprolactinaemic infertile women. METHODS A total of 183 infertile women with hyperprolactinemia undergoing intrauterine insemination (IUI) were randomly divided into two groups. Group A: 94 with bromocriptine and group B:89 with cabergoline. The efficacy and safety was evaluated on the basis of normalization of prolactin levels, normalization of menstrual cycle, disappearance of galactorrhea, occurrence of pregnancy and adverse effects with each of these medications. RESULTS The presence of galactorrhea and irregular menstruation were significantly lower in patients of group B than group A (P<0.001 and P=0.011, respectively) with a significant lower prevalence of side effects in cabergoline group. Pregnancy was significantly more achieved among the women with the treatment of cabergoline (82%) as compared to bromocriptine (56.4%) (P<0.001). CONCLUSIONS Our results suggest that cabergoline treatment in infertile women with prolactinemia is more effective. It lowers prolactin with better tolerability and much more effective in the achievement of pregnancy.

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D007247 Infertility, Female Diminished or absent ability of a female to achieve conception. Sterility, Female,Sterility, Postpartum,Sub-Fertility, Female,Subfertility, Female,Female Infertility,Female Sterility,Female Sub-Fertility,Female Subfertility,Postpartum Sterility,Sub Fertility, Female
D007315 Insemination, Artificial Artificial introduction of SEMEN or SPERMATOZOA into the VAGINA to facilitate FERTILIZATION. Artificial Insemination,Eutelegenesis,Artificial Inseminations,Eutelegeneses,Inseminations, Artificial
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077465 Cabergoline An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE. 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea,1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate,Cabaser,Cabaseril,Cabergoline Diphosphate,Dostinex,FCE 21336,FCE-21336,Galastop
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
October 1994, The New England journal of medicine,
Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
March 1985, Fertility and sterility,
Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
March 2024, Turkish journal of obstetrics and gynecology,
Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
September 2001, Internal medicine (Tokyo, Japan),
Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
March 1998, European journal of endocrinology,
Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
January 2022, American journal of translational research,
Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
January 2014, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology,
Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
August 2003, Fertility and sterility,
Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
January 2019, American journal of therapeutics,
Shahdokht Motazedian, and Lida Babakhani, and Seyed-Mohammad Fereshtehnejad, and Khatereh Mojthahedi
September 2006, Fertility and sterility,
Copied contents to your clipboard!